Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Compass Therapeutics Inc.

    NASDAQ: CMPX · Real-Time Price · USD
    2.24
    -0.13 (-5.49%)
    At close: Jun 17, 2025, 3:02 PM

    Compass Therapeutics Statistics

    Share Statistics

    Compass Therapeutics has 138.28M shares outstanding. The number of shares has increased by 0.5% in one year.

    Shares Outstanding

    n/a
    		 138.28M

    Shares Change (YoY)

    n/a
    		 0.5%

    Shares Change (QoQ)

    n/a
    		 0.5%

    Owned by Institutions (%)

    n/a
    		 73.68%

    Shares Floating

    n/a
    		 87.95M

    Failed to Deliver (FTD) Shares

    n/a
    		 4,956

    FTD / Avg. Volume

    n/a
    		 0.34%

    Short Selling Information

    The latest short interest is 7.43M, so 5.4% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 7.43M

    Short % of Shares Out

    n/a
    		 5.4%

    Short % of Float

    n/a
    		 7.64%

    Short Ratio (days to cover)

    n/a
    		 13.63

    Valuation Ratios

    The PE ratio is -4.66 and the forward PE ratio is -4.31. Compass Therapeutics's PEG ratio is 0.82.

    PE Ratio

    n/a
    		 -4.66

    Forward PE

    n/a
    		 -4.31

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.9

    PB Ratio

    n/a
    		 1.33

    P/FCF Ratio

    n/a
    		 -4.88

    PEG Ratio

    n/a
    		 0.82
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Compass Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 19.73, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 19.73

    Quick Ratio

    n/a
    		 19.73

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 -0.04

    Debt / FCF

    n/a
    		 -0.04

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,214,114.29

    Employee Count

    n/a
    		 35

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 101.71% in the last 52 weeks. The beta is 1.22, so Compass Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.22

    52-Week Price Change

    n/a
    		 101.71%

    50-Day Moving Average

    n/a
    		 1.99

    200-Day Moving Average

    n/a
    		 2.04

    Relative Strength Index (RSI)

    n/a
    		 60.68

    Average Volume (20 Days)

    n/a
    		 1,440,661

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 -1.89M

    Operating Income

    n/a
    		 -50.36M

    Net Income

    n/a
    		 -42.49M

    EBITDA

    n/a
    		 -48.47M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -0.33
    Full Income Statement

    Balance Sheet

    The company has 24.23M in cash and 1.73M in debt, giving a net cash position of 22.5M.

    Cash & Cash Equivalents

    n/a
    		 24.23M

    Total Debt

    n/a
    		 1.73M

    Net Cash

    n/a
    		 22.5M

    Retained Earnings

    n/a
    		 -315.31M

    Total Assets

    n/a
    		 149.15M

    Working Capital

    n/a
    		 136.71M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -40.62M and capital expenditures -30K, giving a free cash flow of -40.65M.

    Operating Cash Flow

    n/a
    		 -40.62M

    Capital Expenditures

    n/a
    		 -30K

    Free Cash Flow

    n/a
    		 -40.65M

    FCF Per Share

    n/a
    		 -0.32
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    CMPX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CMPX is $8, which is 239% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $8

    Price Target Difference

    n/a
    		 239%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 8
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 12.82

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist